

I. AMENDMENTS

Amendments to the Claims:

Please replace all prior listing of claims with the following listing:

1. Canceled.
2. (Currently Amended) A monoclonal antibody which specifically recognizes A β 11-x peptides, wherein said monoclonal antibody specifically recognizes the first 5 to 7 human amino acids of the β -secretase₁₁ cleavage site, i.e., Seq Id No.:1 and Seq Id No.:2 or the first 5 to 7 mouse amino acids of the β -secretase₁₁ cleavage site, i.e. Seq Id No.:3 and Seq Id No.:4, without cross-reacting with full length A β 1-40/42 peptide, as immunogens.
3. (Currently Amended) The monoclonal ~~A α~~ antibody as claimed in claim 2 that is detectably labeled.
4. (Currently Amended) The monoclonal ~~A α~~ antibody as claimed in claim 3 wherein the detectable label is a radiolabel, an enzyme label, a luminescent label or a fluorescent label.
5. (Currently Amended) The monoclonal ~~A α~~ antibody as claimed in claim 2 that is immobilized on a carrier.
6. (Currently Amended) The ~~A~~ monoclonal antibody according to claim 2, expressed by the hybridoma cells J&JPRD/hA β 11/1 and J&JPRD/hA β 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accession numbers LMBP 5896CB and LMBP 5897CB respectively.

7. (Previously Presented) The hybridoma cells J&JPRD/hA β 11/1 and J&JPRD/hA β 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accession numbers LMBP 5896CB and LMBP 5897CB respectively.
8. (Currently Amended) An immunoassay method for the determination or detection of A β 11-x peptides in a sample, the method comprising contacting the sample with an antibody to A β 11-x peptides as claimed in claim 24 and determining whether an immune complex is formed between the antibody and the A β 11-x peptide.
9. (Currently Amended) A method for the detection of the presence of A β 11-x peptides in a tissue sample, the method comprising:
obtaining a tissue sample from the body of a subject;
contacting the tissue sample with an imaging effective amount of ~~the~~ detectably labeled antibody as claimed in claim 3; and
detecting the label to establish the presence of A β 11-x peptides in the tissue sample.
10. (Previously Presented) A method for the detection of the presence of A β 11-x peptides in a tissue sample, the method comprising:
obtaining a tissue sample from the body of a subject;
contacting the tissue sample with an imaging effective amount of a detectably labeled, monoclonal antibody which specifically recognizes A β 11-x peptides; and
detecting the label to establish the presence of A β 11-x peptides in the tissue sample;
wherein the antibody that is detectably labeled, is expressed by at least one of the hybridoma cells as claimed in claim 7.

11. (Currently Amended) A method for the detection of the presence of A β 11-x peptides in a body fluid sample, the method comprising:

obtaining a body fluid sample from the body of a subject;

contacting the body fluid sample with an imaging effective amount of thea detectably labeled antibody as claimed in claim 3; and

detecting the label to establish the presence of A β 11-x peptides in the body fluid sample.
12. Canceled.
13. Canceled.
14. (Currently Amended) A method for the diagnosis of ~~diseases~~a disease associated with production of β -amyloid peptides wherein said disease is selected from the group consisting of clinical or pre-clinical Alzheimer's disease, Down's syndrome, HCHWA-D or cerebral amyloid angiopathy, comprising ~~a step of employing an antibody as claimed in claim 1 to detect a presence of an A β 11-x peptide in a sample~~

obtaining a sample from a subject in need of said diagnosis;

contacting the sample with an effective amount of the detectably labeled antibody as claimed in claim 3; and

detecting the label to determine the presence of A β 11-x peptides in the tissue sample,

wherein a presence of A β 11-x peptides in the sample indicates the presence of said disease.

15. (Currently Amended) A diagnostic composition comprising thean antibody as claimed in claim 24 and a pharmaceutically acceptable carrier.

16. (Currently Amended) An immunoassay kit for the diagnosis of diseasesa disease associated with production of β -amyloid peptides, comprising thean antibody as claimed in claim 2 and support for the antibody, wherein said disease is selected from the group consisting of clinical or pre-clinical Alzheimer's disease, Down's syndrome, HCHWA-D or cerebral amyloid angiopathy.